Home / Health / First Gene Therapy for Childhood Hearing Loss Approved
First Gene Therapy for Childhood Hearing Loss Approved
24 Apr
Summary
- FDA approved the first gene therapy for inherited hearing loss.
- The one-time treatment is for a rare condition affecting up to 50 US babies annually.
- Regeneron will provide the groundbreaking therapy free to US patients.
The US Food and Drug Administration has granted approval for the first-ever gene therapy designed to treat inherited hearing loss. This innovative, one-time treatment targets a rare genetic condition that impacts up to approximately 50 infants born annually in the United States. In clinical trials, the therapy demonstrated remarkable efficacy, significantly improving hearing in a majority of participating children.
Developed by biotechnology firm Regeneron, the therapy, named Otarmeni, is administered via a surgical procedure. The company has committed to providing this life-changing treatment free of charge to patients within the US. This move aims to set a precedent for making advanced biotech innovations accessible to those in need, embodying the potential of scientific advancement to offer profound gifts.
Regeneron plans to seek regulatory approval in other countries. While the therapy itself is free, potential out-of-pocket costs may still apply for the necessary surgical procedure, which is not performed by the company. The FDA's swift review process underscored the agency's commitment to accelerating promising treatments for rare conditions.
